To correct the expected lymphocytopenia by TMZ in such an immunogenic tumour as malignant melanoma, we administrated combined immunotherapy with GM-CSF, low-dose IL2 and IFNα s.c. for 12 days in a dosing schedule determined in a phase I study (De Gast et al, 2000). The gene discussed is IL2; the disease is neoplasm.